Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inhaled corticosteroid use for asthma is linked to adrenal suppression

The largest metabolomic study of asthma thus far, comprising >14,000 people from four independent cohorts, has found that inhaled corticosteroid (ICS) treatment is associated with adrenal suppression, even at low doses. Thus, ICS dosage should be optimized to minimize adrenal suppression while maintaining its established benefits in asthma management.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Overall study design.


  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2021). This report summarizes the recommended changes in asthma treatment guidelines, including suggestions for increased use of low-dose ICSs.

  2. Lapi, F. et al. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur. Respir. J. 42, 79–86 (2013). This review article is on ICSs and the risk of adrenal insufficiency in asthma.

    Article  CAS  PubMed  Google Scholar 

  3. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N. Engl. J. Med. 343, 1054–1063 (2000). This paper reports the results from a four-year RCT of ICS treatment.

  4. Hawcutt, D. B. et al. Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. Lancet Respir. Med. 6, 442–450 (2018). This study is the largest genome-wide association study so far of ICS-induced adrenal suppression.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pietzner, M. et al. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med. 27, 471–479 (2021). This paper is a summary of the EPIC-Norfolk cohort and metabolomics data.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Kachroo, P. et al. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma. Nat. Med. (2021).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Inhaled corticosteroid use for asthma is linked to adrenal suppression. Nat Med 28, 645–646 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing